Woodhouse David J closing all direct ownership in the company (SEC Form 4)
$NGM
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
|
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | ||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | |||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
NGM BIOPHARMACEUTICALS INC [ NGM ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 04/05/2024 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 04/05/2024 | U | 23,993 | D | (1) | 0 | D | |||
| Common Stock | 04/05/2024 | U | 97,654(3) | D | (2) | 0 | I | See footnote(3) | ||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Restricted Stock Unit | (1)(4) | 04/05/2024 | D | 95,400 | (4) | (5) | Common Stock | 95,400 | (1)(4) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 255,000 | (6) | 04/21/2025 | Common Stock | 255,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 87,013 | (6) | 01/19/2027 | Common Stock | 87,013 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 57,833 | (6) | 01/30/2028 | Common Stock | 57,833 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 500,000 | (6) | 07/24/2028 | Common Stock | 500,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 200,000 | (6) | 02/06/2029 | Common Stock | 200,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 400,000 | (6) | 02/03/2030 | Common Stock | 400,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 450,000 | (6) | 03/16/2031 | Common Stock | 450,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $0.84(1)(6) | 04/05/2024 | D | 500,000 | (6) | 03/02/2032 | Common Stock | 500,000 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $4.36(1)(6) | 04/05/2024 | D | 381,600 | (6) | 03/01/2033 | Common Stock | 381,600 | (1)(6) | 0 | D | ||||
| Stock Option (Right to Buy) | $4.36(1)(6) | 04/05/2024 | D | 500,000 | (6) | 03/01/2033 | Common Stock | 500,000 | (1)(6) | 0 | D | ||||
| Explanation of Responses: |
| 1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of $1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price"). |
| 2. Disposed of pursuant to a Rollover Agreement between, inter alia, Dr. Woodhouse, Parent and Purchaser, in exchange for shares in Parent. |
| 3. Shares held by The Woodhouse Family Trust 9/8/05. |
| 4. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, as of the Effective Time, each outstanding Restricted Stock Unit was canceled and the holder of such canceled Restricted Stock Unit was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the Offer Price. |
| 5. Restricted Stock Units do not have an expiration date. |
| 6. Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option. Each Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration. |
| /s/ Valerie Pierce, Attorney-in-Fact | 04/05/2024 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||